Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with ?-interferon and ribavirin

Marco Vacante; Cristina Russo; Maria Gargante; Maria Giordano; Gaetano Bertino; Sergio Neri; Mariano Malaguarnera; Fabio Galvano; Giovanni Volti; Mariano Malaguarnera

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with ?-interferon and ribavirin

Author(s):

Marco Vacante,

Cristina Russo,

Maria Gargante,

Maria Giordano,

Gaetano Bertino,

Sergio Neri,

Mariano Malaguarnera,

Fabio Galvano,

Giovanni Volti,

Mariano Malaguarnera^1,*

1Department of Internal Medicine and Systemic diseases, University of Catania, Catania, Italy

Hepatitis Monthly:Vol. 11, issue 2; 92-98

Published online:Feb 28, 2011

Article type:Research Article

Received:Feb 15, 2010

Accepted:Aug 14, 2010

How to Cite:Vacante M, Russo C, Gargante M, Giordano M, Bertino G, et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with ?-interferon and ribavirin. Hepat Mon. 2011;11(2):. doi:

Abstract

Background: Nonalcoholic fatty liver disease develops in patients with chronic hepatitis C. Interferon and ribavirin combination therapy is the standard treatment for chronic hepatitis C, but if present, NAFLD can reduce the virological response to anti-HCV therapies.
Objectives: We determined whether the addition of rosuvastatin to interferon and ribavirin improves the sustained virological response (SVR) and reduces steatosis.
Patients and Methods: This study was a prospective, randomized, open-label trial. Between January 2004 and December 2007, 65 patients with chronic hepatitis (27 women and 38 men, mean age 48 years) aged 32-63 years (median 46 years) were consecutively enrolled. Patients were randomly assigned to receive leukocyte interferon alpha (3 MIU 3 times per week) plus ribavirin (1200 mg per day) for 12 months or interferon alpha and ribavirin at the same dosages plus rosuvastatin (5 mg per day). The primary endpoints were measurements in SVR, liver enzyme, cholesterol, triglyceride, CRP, glucose, and insulin levels; and Homa-IR, fibrosis, and steatosis scores.
Results: After 12 months of treatment, we observed a significant improvement in SVR in 51% of patients who received interferon plus ribavirin plus rosuvastatin compared with 18% of relapsers (OR 1.52; 95% CI= 0.41-5.64; RR 1.13). There were 23 responders (69%) and 10 nonresponders (30%) (OR 1.38; 95% CI= 0.49-16.5; RR 1.11). When comparing interferon plus ribavirin group vs interferon plus ribavirin and rosuvastatin group after 12 months, we observed a significant difference in AST (85.70 vs.106.5.00 IU/ml) (OR 1.2; 95% CI= 0.29-4.94; RR 1.04; p<0.001), ALT (81.80 vs. 126.2 IU/ml) (OR 1.2; 95% CI= 0.29-4.94; RR 1.04; p<0.001), LDL-cholesterol (0.01 vs. 0.60 mmol/l) (OR 14; 95% CI= 3.98-49.16; p RR 2.96; <0.001), triglycerides (0.17 vs. 0.2 mmol/l) (OR 20; 95% CI= 4.94-80.89; RR 5.38; p<0.05), and Viremia (1.8 vs. 2.48 UI/ml, p<0.05). Mean fibrosis score decreased 0.10 vs. 0.50 (OR 4.5; 95% CI= 0.89-22.66; RR 1.5; p<0.05), and mean steatosis score declined 0.30 vs. 0.50 (OR 11.2; CI= 2.88-43.53; RR 2.75; p<0.001).
Conclusions: In HCV patients with NAFLD, the addition of rosuvastatin to interferon and ribavirin significantly reduces viremia, steatosis, and fibrosis without causing side effects.

Keywords

Fulltext

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 20 hours ago
Scopus by Title: 0
Last Update: 20 hours ago
Scopus by Title (Ref): 0
Last Update: 15 years ago
CrossRef: 0
Last Update: 1 day ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Marco Vacante:[PubMed][Scholar]
Cristina Russo:[PubMed][Scholar]
Maria Gargante:[PubMed][Scholar]
Maria Giordano:[PubMed][Scholar]
Gaetano Bertino:[PubMed][Scholar]
Sergio Neri:[PubMed][Scholar]
Mariano Malaguarnera:[PubMed][Scholar]
Fabio Galvano:[PubMed][Scholar]
Giovanni Volti:[PubMed][Scholar]
Mariano Malaguarnera:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with ?-interferon and ribavirin

Abstract

Fulltext

Last Update: 20 hours ago

Last Update: 20 hours ago

Last Update: 15 years ago

Last Update: 1 day ago